Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galvokimig dose-ranging study in adults with moderate to severe atopic dermatitis
jRCT2031250619Active, not recruiting
- Sponsor
- UCB
- Start
- Mar 2026
- Modality
- Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised, double-blind trial of galvokimig in atopic dermatitis (AD) (4 arms), sponsored by UCB. Primary endpoint: EASI75 response at Week 16. Started Mar 2026; status: active, not recruiting.
02
Drugs
galvokimig
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2031250619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250619.